JGC
CMTA

J. Goldman & Co’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

J. Goldman & Co’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,692
Closed -$488K – 485
2017
Q4 		$488K Buy
+25,692
New +$430K 0.03% 270

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

J. Goldman & Co's CMTA Position: Q1 2018 in Review

J. Goldman & Co sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q1 2018, closing a stake of 25,692 shares — an estimated $488K sold.

J. Goldman & Co first reported a position in CMTA in Q4 2017 and held it in 1 quarter. The position peaked at $488K in Q4 2017. 38 funds tracked by Wall St. Rank hold CMTA as of Q1 2018.

  • J. Goldman & Co reported no remaining Clementia Pharmaceuticals Inc. position as of Q1 2018 after selling out during the quarter.
  • J. Goldman & Co sold 25,692 Clementia Pharmaceuticals Inc. shares in Q1 2018, an estimated $488K.
  • J. Goldman & Co first reported a position in Clementia Pharmaceuticals Inc. in Q4 2017 and held it in 1 quarter.
  • J. Goldman & Co's Clementia Pharmaceuticals Inc. position peaked at $488K in Q4 2017.
  • 38 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q1 2018.

Based on J. Goldman & Co's 13F filing for Q1 2018, filed 15 May 2018.